Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

Capgras Syndrome in Advanced Parkinson's Disease.

Groth CL, Pusso A, Sperling SA, Huss DS, Elias WJ, Wooten GF, Barrett MJ.

J Neuropsychiatry Clin Neurosci. 2018 Spring;30(2):160-163. doi: 10.1176/appi.neuropsych.17030052. Epub 2017 Nov 14.

PMID:
29132271
2.

MM1-Type Sporadic Creutzfeldt-Jakob Disease With Early Behavioral Changes and Prolonged Symptom Duration.

Crowell JL, Wooten GF, Barrett MJ.

J Neuropsychiatry Clin Neurosci. 2016 Spring;28(2):e31-2. doi: 10.1176/appi.neuropsych.15120404. No abstract available.

PMID:
27093388
3.

Relationship of age of onset and family history in Parkinson disease.

Barrett MJ, Hac NE, Yan G, Harrison MB, Wooten GF.

Mov Disord. 2015 Apr 15;30(5):733-5. doi: 10.1002/mds.26166. Epub 2015 Mar 4.

PMID:
25737058
4.

Mortality in levodopa-treated Parkinson's disease.

Morgan JC, Currie LJ, Harrison MB, Bennett JP Jr, Trugman JM, Wooten GF.

Parkinsons Dis. 2014;2014:426976. doi: 10.1155/2014/426976. Epub 2014 Jan 28.

5.

Gamma Knife thalamotomy.

Kassell NF, Wooten GF.

J Neurosurg. 2013 Aug;119(2):531-2. doi: 10.3171/2013.4.JNS13802. Epub 2013 Jun 21. No abstract available.

PMID:
23790117
6.

Differential susceptibility to motor impulsivity among functional subtypes of Parkinson's disease.

Wylie SA, van den Wildenberg W, Ridderinkhof KR, Claassen DO, Wooten GF, Manning CA.

J Neurol Neurosurg Psychiatry. 2012 Dec;83(12):1149-54. doi: 10.1136/jnnp-2012-303056. Epub 2012 Aug 23.

7.

Hypertrophic olivary degeneration.

Bruno MK, Wooten GF.

Arch Neurol. 2012 Feb;69(2):274-5. doi: 10.1001/archneurol.2011.657. No abstract available.

PMID:
22332198
8.

The risky business of dopamine agonists in Parkinson disease and impulse control disorders.

Claassen DO, van den Wildenberg WPM, Ridderinkhof KR, Jessup CK, Harrison MB, Wooten GF, Wylie SA.

Behav Neurosci. 2011 Aug;125(4):492-500. doi: 10.1037/a0023795.

9.

Handedness and motor symptom asymmetry in Parkinson's disease.

Barrett MJ, Wylie SA, Harrison MB, Wooten GF.

J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1122-4. doi: 10.1136/jnnp.2010.209783. Epub 2010 Sep 22.

10.

Central nervous system involvement in axonal Charcot-Marie-Tooth disease.

Du X, Wooten GF, Matsumoto JA, Phillips LH 2nd.

Muscle Nerve. 2010 Jan;41(1):148-50. doi: 10.1002/mus.21524. No abstract available.

PMID:
19813192
11.

The effect of speed-accuracy strategy on response interference control in Parkinson's disease.

Wylie SA, van den Wildenberg WP, Ridderinkhof KR, Bashore TR, Powell VD, Manning CA, Wooten GF.

Neuropsychologia. 2009 Jul;47(8-9):1844-53. doi: 10.1016/j.neuropsychologia.2009.02.025. Epub 2009 Feb 28.

12.

Autosomal dominant subcortical gliosis presenting as frontotemporal dementia.

Swerdlow RH, Miller BB, Lopes MB, Mandell JW, Wooten GF, Damgaard P, Manning C, Fowler M, Brashear HR.

Neurology. 2009 Jan 20;72(3):260-7. doi: 10.1212/01.wnl.0000339484.61490.a4.

PMID:
19153373
13.

The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.

Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Goldwurm S, Pezzoli G, Zini M, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Laramie JM, DeStefano AL, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.

BMC Med. 2008 Nov 5;6:32. doi: 10.1186/1741-7015-6-32.

14.

UPDRS activity of daily living score as a marker of Parkinson's disease progression.

Harrison MB, Wylie SA, Frysinger RC, Patrie JT, Huss DS, Currie LJ, Wooten GF.

Mov Disord. 2009 Jan 30;24(2):224-30. doi: 10.1002/mds.22335.

15.

The effect of Parkinson's disease on interference control during action selection.

Wylie SA, van den Wildenberg WP, Ridderinkhof KR, Bashore TR, Powell VD, Manning CA, Wooten GF.

Neuropsychologia. 2009 Jan;47(1):145-57. doi: 10.1016/j.neuropsychologia.2008.08.001. Epub 2008 Aug 9.

16.

Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study.

McNicoll CF, Latourelle JC, MacDonald ME, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Saint-Hilaire MH, Massood T, Huskey KW, DeStefano AL, Gillis T, Mysore J, Goldwurm S, Pezzoli G, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-Hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.

Mov Disord. 2008 Aug 15;23(11):1596-601. doi: 10.1002/mds.22186.

17.

Replication of association between ELAVL4 and Parkinson disease: the GenePD study.

DeStefano AL, Latourelle J, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts R, Guttman M, Racette BA, Perlmutter JS, Marlor L, Shill HA, Singer C, Goldwurm S, Pezzoli G, Saint-Hilaire MH, Hendricks AE, Gower A, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-Hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.

Hum Genet. 2008 Aug;124(1):95-9. doi: 10.1007/s00439-008-0526-4. Epub 2008 Jun 29.

18.

Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study.

Tobin JE, Latourelle JC, Lew MF, Klein C, Suchowersky O, Shill HA, Golbe LI, Mark MH, Growdon JH, Wooten GF, Racette BA, Perlmutter JS, Watts R, Guttman M, Baker KB, Goldwurm S, Pezzoli G, Singer C, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Laramie JM, DeStefano AL, Litvan I, Nicholson G, Corbett A, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Sherman S, Al-hinti J, Drasby E, Nance M, Moller AT, Ostergaard K, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.

Neurology. 2008 Jul 1;71(1):28-34. doi: 10.1212/01.wnl.0000304051.01650.23. Epub 2008 May 28.

19.

Validity, sensitivity and specificity of the mentation, behavior and mood subscale of the UPDRS.

Holroyd S, Currie LJ, Wooten GF.

Neurol Res. 2008 Jun;30(5):493-6. doi: 10.1179/016164107X251772.

PMID:
18241530
20.

G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy.

Ozelius LJ, Foroud T, May S, Senthil G, Sandroni P, Low PA, Reich S, Colcher A, Stern MB, Ondo WG, Jankovic J, Huang N, Tanner CM, Novak P, Gilman S, Marshall FJ, Wooten GF, Chelimsky TC, Shults CW; North American Multiple System Atrophy Study Group.

Mov Disord. 2007 Mar 15;22(4):546-9.

21.

Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study.

Wilk JB, Tobin JE, Suchowersky O, Shill HA, Klein C, Wooten GF, Lew MF, Mark MH, Guttman M, Watts RL, Singer C, Growdon JH, Latourelle JC, Saint-Hilaire MH, DeStefano AL, Prakash R, Williamson S, Berg CJ, Sun M, Goldwurm S, Pezzoli G, Racette BA, Perlmutter JS, Parsian A, Baker KB, Giroux ML, Litvan I, Pramstaller PP, Nicholson G, Burn DJ, Chinnery PF, Vieregge P, Slevin JT, Cambi F, MacDonald ME, Gusella JF, Myers RH, Golbe LI.

Neurology. 2006 Dec 26;67(12):2206-10.

PMID:
17190945
22.

Preliminary FMRI evidence of visual system dysfunction in Parkinson's disease patients with visual hallucinations.

Holroyd S, Wooten GF.

J Neuropsychiatry Clin Neurosci. 2006 Summer;18(3):402-4.

PMID:
16963591
23.

Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study.

Sun M, Latourelle JC, Wooten GF, Lew MF, Klein C, Shill HA, Golbe LI, Mark MH, Racette BA, Perlmutter JS, Parsian A, Guttman M, Nicholson G, Xu G, Wilk JB, Saint-Hilaire MH, DeStefano AL, Prakash R, Williamson S, Suchowersky O, Labelle N, Growdon JH, Singer C, Watts RL, Goldwurm S, Pezzoli G, Baker KB, Pramstaller PP, Burn DJ, Chinnery PF, Sherman S, Vieregge P, Litvan I, Gillis T, MacDonald ME, Myers RH, Gusella JF.

Arch Neurol. 2006 Jun;63(6):826-32.

PMID:
16769863
24.

Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.

Tilley BC, Palesch YY, Kieburtz K, Ravina B, Huang P, Elm JJ, Shannon K, Wooten GF, Tanner CM, Goetz GC; NET-PD Investigators.

Neurology. 2006 Mar 14;66(5):628-33. Review.

PMID:
16534099
25.

GDNF in treatment of Parkinson's disease: response to editorial.

Lang AE, Langston JW, Stoessl AJ, Brodsky M, Brooks DJ, Dhawan V, Elias WJ, Lozano AM, Moro E, Nutt JG, Stacy M, Turner D, Wooten GF.

Lancet Neurol. 2006 Mar;5(3):200-2. No abstract available.

PMID:
16488373
26.

BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study.

Karamohamed S, Latourelle JC, Racette BA, Perlmutter JS, Wooten GF, Lew M, Klein C, Shill H, Golbe LI, Mark MH, Guttman M, Nicholson G, Wilk JB, Saint-Hilaire M, DeStefano AL, Prakash R, Tobin S, Williamson J, Suchowersky O, Labell N, Growdon BN, Singer C, Watts R, Goldwurm S, Pezzoli G, Baker KB, Giroux ML, Pramstaller PP, Burn DJ, Chinnery P, Sherman S, Vieregge P, Litvan I, Gusella JF, Myers RH, Parsian A.

Neurology. 2005 Dec 13;65(11):1823-5.

PMID:
16344533
27.

Clinical practice. Diagnosis and initial management of Parkinson's disease.

Nutt JG, Wooten GF.

N Engl J Med. 2005 Sep 8;353(10):1021-7. Review. No abstract available.

PMID:
16148287
28.

Depression is associated with impairment of ADL, not motor function in Parkinson disease.

Holroyd S, Currie LJ, Wooten GF.

Neurology. 2005 Jun 28;64(12):2134-5.

PMID:
15985588
29.

Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study.

Karamohamed S, Golbe LI, Mark MH, Lazzarini AM, Suchowersky O, Labelle N, Guttman M, Currie LJ, Wooten GF, Stacy M, Saint-Hilaire M, Feldman RG, Liu J, Shoemaker CM, Wilk JB, DeStefano AL, Latourelle JC, Xu G, Watts R, Growdon J, Lew M, Waters C, Vieregge P, Pramstaller PP, Klein C, Racette BA, Perlmutter JS, Parsian A, Singer C, Montgomery E, Baker K, Gusella JF, Herbert A, Myers RH.

Mov Disord. 2005 Sep;20(9):1188-91.

PMID:
15966003
30.

A responsive outcome for Parkinson's disease neuroprotection futility studies.

Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K; NET-PD Investigators.

Ann Neurol. 2005 Feb;57(2):197-203.

PMID:
15668964
31.

Amphetamine-induced chorea in attention deficit-hyperactivity disorder.

Morgan JC, Winter WC, Wooten GF.

Mov Disord. 2004 Jul;19(7):840-842. doi: 10.1002/mds.20081.

PMID:
15254949
32.

Hyponatremia due to an additive effect of carbamazepine and thiazide diuretics.

Ranta A, Wooten GF.

Epilepsia. 2004 Jul;45(7):879. No abstract available.

33.

Postmenopausal estrogen use affects risk for Parkinson disease.

Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF.

Arch Neurol. 2004 Jun;61(6):886-8.

PMID:
15210525
34.

Are men at greater risk for Parkinson's disease than women?

Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J.

J Neurol Neurosurg Psychiatry. 2004 Apr;75(4):637-9.

35.

A haplotype at the PARK3 locus influences onset age for Parkinson's disease: the GenePD study.

Karamohamed S, DeStefano AL, Wilk JB, Shoemaker CM, Golbe LI, Mark MH, Lazzarini AM, Suchowersky O, Labelle N, Guttman M, Currie LJ, Wooten GF, Stacy M, Saint-Hilaire M, Feldman RG, Sullivan KM, Xu G, Watts R, Growdon J, Lew M, Waters C, Vieregge P, Pramstaller PP, Klein C, Racette BA, Perlmutter JS, Parsian A, Singer C, Montgomery E, Baker K, Gusella JF, Fink SJ, Myers RH, Herbert A; GenePD study.

Neurology. 2003 Dec 9;61(11):1557-61.

PMID:
14663042
36.

Dystonia with and without deafness is caused by TIMM8A mutation.

Swerdlow RH, Juel VC, Wooten GF.

Adv Neurol. 2004;94:147-54. Review. No abstract available.

PMID:
14509668
37.

Agonists vs levodopa in PD: the thrilla of whitha.

Wooten GF.

Neurology. 2003 Feb 11;60(3):360-2. No abstract available.

PMID:
12578913
38.

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr, Lozano AM, Penn RD, Simpson RK Jr, Stacy M, Wooten GF; ICV GDNF Study Group. Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor.

Neurology. 2003 Jan 14;60(1):69-73.

PMID:
12525720
39.

Segregation analysis of Parkinson disease revealing evidence for a major causative gene.

Maher NE, Currie LJ, Lazzarini AM, Wilk JB, Taylor CA, Saint-Hilaire MH, Feldman RG, Golbe LI, Wooten GF, Myers RH.

Am J Med Genet. 2002 May 1;109(3):191-7.

PMID:
11977177
40.

PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study.

DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M, Montgomery E, Waters CH, Singer C, Watts RL, Currie LJ, Wooten GF, Maher NE, Wilk JB, Sullivan KM, Slater KM, Saint-Hilaire MH, Feldman RG, Suchowersky O, Lafontaine AL, Labelle N, Growdon JH, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Reider CR, Stacy M, MacDonald ME, Gusella JF, Myers RH.

Am J Hum Genet. 2002 May;70(5):1089-95. Epub 2002 Mar 27.

41.

Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study.

Maher NE, Golbe LI, Lazzarini AM, Mark MH, Currie LJ, Wooten GF, Saint-Hilaire M, Wilk JB, Volcjak J, Maher JE, Feldman RG, Guttman M, Lew M, Waters CH, Schuman S, Suchowersky O, Lafontaine AL, Labelle N, Vieregge P, Pramstaller PP, Klein C, Hubble J, Reider C, Growdon J, Watts R, Montgomery E, Baker K, Singer C, Stacy M, Myers RH.

Neurology. 2002 Jan 8;58(1):79-84. Erratum in: Neurology. 2002 Apr 9;58(7):1136.

PMID:
11781409
42.

Amoxicillin-induced aseptic meningitis.

Wittmann A, Wooten GF.

Neurology. 2001 Nov 13;57(9):1734. No abstract available.

PMID:
11706130
43.
44.

Genome-wide scan for Parkinson's disease: the GenePD Study.

DeStefano AL, Golbe LI, Mark MH, Lazzarini AM, Maher NE, Saint-Hilaire M, Feldman RG, Guttman M, Watts RL, Suchowersky O, Lafontaine AL, Labelle N, Lew MF, Waters CH, Growdon JH, Singer C, Currie LJ, Wooten GF, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Stacy M, Montgomery E, MacDonald ME, Gusella JF, Myers RH.

Neurology. 2001 Sep 25;57(6):1124-6.

PMID:
11571351
45.
46.

Maternal age is not a risk factor for Parkinson's disease.

Currie LJ, Harrison MB, Trugman JM, Bennett JP, Swerdlow RH, Manning CA, Wooten GF.

J Neurol Neurosurg Psychiatry. 2001 Jul;71(1):130-1. No abstract available.

47.

Prospective study of hallucinations and delusions in Parkinson's disease.

Holroyd S, Currie L, Wooten GF.

J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):734-8.

48.

Gender ratio differences between Parkinson's disease patients and their affected relatives.

Swerdlow RH, Parker WD, Currie LJ, Bennett JP, Harrison MB, Trugman JM, Wooten GF.

Parkinsonism Relat Disord. 2001 Apr;7(2):129-133.

PMID:
11248594
49.

Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy.

Swerdlow RH, Golbe LI, Parks JK, Cassarino DS, Binder DR, Grawey AE, Litvan I, Bennett JP Jr, Wooten GF, Parker WD.

J Neurochem. 2000 Oct;75(4):1681-4.

50.

Parkinson disease in twins.

Parker WD Jr, Swerdlow RH, Parks JK, Davis JN 2nd, Trimmer P, Bennett JP, Wooten GF.

JAMA. 1999 Oct 13;282(14):1328; author reply 1328-9. No abstract available.

PMID:
10527169

Supplemental Content

Loading ...
Support Center